Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro
Source abstract
Abstract
Programmable nucleic acid nanoparticles (NANPs) with precisely controlled functional compositions can regulate the conditional activation of various biological pathways and responses in human cells. However, the intracellular delivery of NANPs alone is hindered by their susceptibility to nuclease activity and inefficient crossing of biological membranes. In this work, we optimized the internalization and therapeutic performance of several representative NANPs delivered with mesoporous silica nanoparticles (MSNPs) tailored for efficient electrostatic association with NANPs. We compared the immunostimulatory properties of different NA-MS-NP complexes formed with globular, planar, and fibrous NANPs and demonstrated the maximum immunostimulation for globular NANPs. As a proof of concept, we assessed the specific gene silencing by NA-MS-NP complexes functionalized with siRNA targeting green fluorescent protein expressed in triple-negative human breast cancer cells. We showed that the fibrous NANPs have the highest silencing efficiency when compared to globular or planar counterparts. Finally, we confirmed the multimodal ability of MSNPs to co-deliver a chemotherapy drug, doxorubicin, and NANPs targeting apoptosis regulator gene BCL2 in triple-negative breast cancer and melanoma cell lines. Overall, the combination of NANPs and MSNPs may become a new promising approach to efficiently treat cancer and other diseases via the simultaneous targeting of various pathways.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, The University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States
Nanoscale Science Program, The University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States
The Center for Biomedical Engineering and Science, The University of North Carolina at Charlotte, Charlotte, North Carolina 28223, United States
Funding
University of North Carolina at Charlotte · National Institute of General Medical Sciences · Division of Materials Research
References (70)
Show source-provided references
1. 10.1038/3507810710.1038/35078107 ↗
2. 10.1038/nchembio83910.1038/nchembio839 ↗
3. 10.1056/NEJMoa171615310.1056/NEJMoa1716153 ↗
4. 10.1038/mtna.2015.3610.1038/mtna.2015.36 ↗
5. 10.5681/apb.2014.04610.5681/apb.2014.046 ↗
6. 10.1038/nrc296610.1038/nrc2966 ↗
7. 10.1038/nnano.2010.23110.1038/nnano.2010.231 ↗
8. 10.1021/acscombsci.6b0007310.1021/acscombsci.6b00073 ↗
9. 10.1016/j.ymeth.2013.10.01310.1016/j.ymeth.2013.10.013 ↗
10. 10.1021/nl302302e10.1021/nl302302e ↗
11. Kireeva M. L. · 2017 · 1632 · 9110.1007/978-1-4939-7138-1_6 ↗
12. 10.1038/nprot.2011.41810.1038/nprot.2011.418 ↗
13. 10.1021/ar400329z10.1021/ar400329z ↗
14. 10.1038/nnano.2010.16010.1038/nnano.2010.160 ↗
15. 10.1002/adfm.20180595910.1002/adfm.201805959 ↗
16. 10.1093/nar/gky121510.1093/nar/gky1215 ↗
17. 10.3390/nano904061110.3390/nano9040611 ↗
18. 10.1021/acs.nanolett.8b0128310.1021/acs.nanolett.8b01283 ↗
19. 10.3390/molecules2406109410.3390/molecules24061094 ↗
20. 10.1016/j.copbio.2019.10.01110.1016/j.copbio.2019.10.011 ↗
21. 10.1093/nar/gku51610.1093/nar/gku516 ↗
22. 10.1002/wnan.158210.1002/wnan.1582 ↗
23. 10.1093/nar/gkx00810.1093/nar/gkx008 ↗
24. 10.1016/bs.mie.2014.10.05810.1016/bs.mie.2014.10.058 ↗
25. 10.1021/acssensors.6b0035210.1021/acssensors.6b00352 ↗
26. 10.1021/acsnano.7b0492310.1021/acsnano.7b04923 ↗
27. 10.1016/j.nano.2019.10209410.1016/j.nano.2019.102094 ↗
28. 10.1039/C8NR04254C10.1039/C8NR04254C ↗
29. 10.1002/smll.20090178910.1002/smll.200901789 ↗
30. 10.1080/17425247.2019.166278610.1080/17425247.2019.1662786 ↗
31. 10.1080/17425247.2016.122929810.1080/17425247.2016.1229298 ↗
32. 10.1039/c2cs15229k10.1039/c2cs15229k ↗
33. 10.1002/adma.20160463410.1002/adma.201604634 ↗
34. 10.1039/C6BM00872K10.1039/C6BM00872K ↗
35. 10.1016/j.actbio.2018.05.05410.1016/j.actbio.2018.05.054 ↗
36. 10.1021/acsami.9b0070410.1021/acsami.9b00704 ↗
37. 10.1039/C9TB01845J10.1039/C9TB01845J ↗
38. 10.1007/978-1-62703-056-4_1410.1007/978-1-62703-056-4_14 ↗
39. 10.1016/S0304-3991(03)00053-610.1016/S0304-3991(03)00053-6 ↗
40. 10.3390/nano504230210.3390/nano5042302 ↗
41. 10.1166/jbn.2016.231810.1166/jbn.2016.2318 ↗
42. 10.2147/IJN.S11819610.2147/IJN.S118196 ↗
43. 10.1039/c1nr10580a10.1039/c1nr10580a ↗
44. 10.1021/acsami.5b0948310.1021/acsami.5b09483 ↗
45. 10.1021/nn100690m10.1021/nn100690m ↗
46. 10.3390/nano704007710.3390/nano7040077 ↗
47. 10.1021/nl104271s10.1021/nl104271s ↗
48. 10.1016/j.micron.2017.03.01910.1016/j.micron.2017.03.019 ↗
49. 10.1016/j.micron.2010.06.00310.1016/j.micron.2010.06.003 ↗
50. 10.1016/j.nano.2016.12.01810.1016/j.nano.2016.12.018 ↗
51. 10.3389/fimmu.2014.0046110.3389/fimmu.2014.00461 ↗
52. 10.1093/jrr/rrs09810.1093/jrr/rrs098 ↗
53. 10.1172/JCI3771610.1172/JCI37716 ↗
54. 10.3390/molecules2205078210.3390/molecules22050782 ↗
55. 10.1002/smll.20110044210.1002/smll.201100442 ↗
56. 10.1016/j.ijpharm.2013.03.02210.1016/j.ijpharm.2013.03.022 ↗
57. 10.1039/C5TB02079D10.1039/C5TB02079D ↗
58. 10.4103/2230-973X.16084410.4103/2230-973X.160844 ↗
59. 10.1039/C7CS00479F10.1039/C7CS00479F ↗
60. 10.1016/j.omtn.2017.03.00710.1016/j.omtn.2017.03.007 ↗
61. 10.1158/0008-5472.CAN-04-000110.1158/0008-5472.CAN-04-0001 ↗
62. 10.3892/ijo_0000015310.3892/ijo_00000153 ↗
63. 10.18632/oncotarget.2537010.18632/oncotarget.25370 ↗
64. 10.3892/mmr.2018.975310.3892/mmr.2018.9753 ↗
65. 10.1021/nn404792510.1021/nn4047925 ↗
66. 10.1002/smll.20090062110.1002/smll.200900621 ↗
67. 10.1021/acsami.8b1339310.1021/acsami.8b13393 ↗
68. 10.1038/mtna.2013.4510.1038/mtna.2013.45 ↗
69. 10.1186/1472-6882-13-16610.1186/1472-6882-13-166 ↗
70. 10.1021/acs.jpcc.6b0675910.1021/acs.jpcc.6b06759 ↗